Related Experiment Videos
Protective effects of beta blockade on pulmonary function when intracranial pressure is elevated
Critical Care Medicine
|May 1, 1983
Summary
Elevated intracranial pressure (ICP) triggers harmful catecholamine (CA) release, impacting pulmonary function. Beta-blocker treatment reversed these adverse effects, suggesting a potential therapy for head injury patients.
Area of Science:
- Neuroscience
- Cardiology
- Pulmonary Medicine
Background:
- Intracranial pressure (ICP) elevation is a critical concern in traumatic brain injury.
- Sympathetic nervous system overactivity and its cardiopulmonary effects are not fully understood in this context.
Purpose of the Study:
- To investigate the cardiopulmonary and catecholamine (CA) responses to acutely increased ICP in a canine model.
- To evaluate the therapeutic potential of beta-blockade in mitigating these responses.
Main Methods:
- Dogs underwent hyperosmolar intracerebral infusion to increase ICP.
- Cardiopulmonary parameters and endogenous catecholamines were monitored for 4 hours.
- A subset of dogs received propranolol (a beta-blocker) after ICP elevation.
Main Results:
- Increased ICP led to sustained elevations in catecholamines, pulmonary vascular pressures, pulmonary blood volume, and venous admixture.
- Propranolol treatment normalized pulmonary pressures and venous admixture despite continued catecholamine increase.
- Beta-blockade reduced cardiac output and heart rate but increased systemic vascular resistance.
Conclusions:
- Sustained increases in catecholamines due to elevated ICP adversely affect pulmonary hemodynamics and shunting.
- Selective beta-blockade effectively reverses these detrimental pulmonary effects.
- Beta-blockade may be a valuable therapeutic strategy for patients with head injuries exhibiting sympathetic overactivity and hypoxemia.